<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/39E6A660-94BC-427C-9ACD-28C18EDFA36E"><gtr:id>39E6A660-94BC-427C-9ACD-28C18EDFA36E</gtr:id><gtr:name>Proveca Limited</gtr:name><gtr:address><gtr:line1>DARESBURY INNOVATION CENTRE KECKWICK LANE , DARESBURY</gtr:line1><gtr:city>WARRINGTON</gtr:city><gtr:postCode>WA4 4FS</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/39E6A660-94BC-427C-9ACD-28C18EDFA36E" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>39E6A660-94BC-427C-9ACD-28C18EDFA36E</gtr:id><gtr:name>Proveca Limited</gtr:name><gtr:address><gtr:line1>DARESBURY INNOVATION CENTRE KECKWICK LANE , DARESBURY</gtr:line1><gtr:city>WARRINGTON</gtr:city><gtr:postCode>WA4 4FS</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>143090.0</gtr:offerGrant><gtr:projectCost>190787.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/AFE0EF89-A983-496A-8188-2A37A54ACE82"><gtr:id>AFE0EF89-A983-496A-8188-2A37A54ACE82</gtr:id><gtr:firstName>Clare</gtr:firstName><gtr:surname>Gleeson</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=131265"><gtr:id>A4A94307-03F1-427D-9F7F-A288C5173246</gtr:id><gtr:title>Novel age appropriate oral liquid formulation of tacrolimus</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Feasibility Studies</gtr:grantCategory><gtr:grantReference>131265</gtr:grantReference><gtr:abstractText>The recognition of the rights of children to have access to safe and effective drugs and the needs of healthcare providers to receive age-appropriate drug information continues to have a major effect on all areas of paediatric pharmaceuticals. In line with this challenge, Proveca?s objective is to develop a new dosage formula of an off patent immunosuppressant which is mainly used following organ transplantation. Children represent a distinct group of organ transplant candidates differing from adults in several important aspects, including pharmacokinetic handling of immunosuppressants and the immune response following organ transplantation. This feasibility project will explore and evaluate the commercial potential and technical feasibility of a licenced paediatric formulation of the immunosuppressant (comprehensive primary and secondary market research, clinical and non-clinical literature reviews, initial experimental studies etc). A development pathway will be identified.</gtr:abstractText><gtr:fund><gtr:end>2014-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2013-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>143090</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">131265</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>